Archive
Access the archives to find the information you want
Sign up or login to unlock the full suite of MEDICALLY features
Mar 6
/
Roche and Genentech
Phase III Randomized COMMODORE 1 Trial: 2-Year Safety and Efficacy of Crovalimab▼ in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched From Eculizumab
At the primary analysis, the global, randomized, Phase III COMMODORE 1 study showed that crovalimab▼ was well tolerated and had similar exploratory efficacy in patients with paroxysmal nocturnal hemoglobinuria who switched from eculizumab to crovalimab▼ compared with those who continued receiving eculizumab. This poster reports long-term efficacy and safety data from COMMODORE 1, with a median follow-up duration of 2 years.
Sign up or login to unlock the full suite of MEDICALLY features
Mar 6
/
Roche and Genentech
Phase III Randomized COMMODORE 2 Trial: 2-Year Efficacy and Safety of Crovalimab▼ in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Naive to Complement Inhibition
At the primary analysis, the global, randomized, Phase III COMMODORE 2 study demonstrated the non-inferior efficacy of crovalimab▼ vs eculizumab for co-primary efficacy endpoints of hemolysis control and transfusion avoidance in patients naive to complement inhibition, with a comparable safety profile. This poster reports long-term efficacy and safety data from COMMODORE 2, with a median follow-up duration of 2 years.
Sign up or login to unlock the full suite of MEDICALLY features
Mar 6
/
Roche and Genentech
Phase III COMMODORE 1 Trial: 2-Year Efficacy and Safety of Crovalimab▼ (Crova) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Ravulizumab (Ravu)
The global, randomized Phase III COMMODORE 1 study showed similar safety and exploratory efficacy for crovalimab▼ vs eculizumab in randomized patients who received prior eculizumab treatment; this study also enrolled non-randomized patients who switched from ravulizumab to crovalimab▼. This poster reports efficacy and safety data from the COMMODORE 1 ravulizumab switch cohort, with a median treatment duration of approximately 2 years.
Sign up or login to unlock the full suite of MEDICALLY features
Mar 6
/
Roche and Genentech
Third OS interim analysis from BEAT-SC: Addition of bevacizumab to atezolizumab & chemotherapy in patients with ES-SCLC
The Phase III BEAT-SC study is evaluating bevacizumab + atezolizumab and carboplatin/cisplatin
and etoposide (ACE) vs placebo + ACE in patients with untreated ES-SCLC from Japan and China.
This presentation reports the third OS interim analysis and additional updated clinical data from
BEAT-SC.
Sign up or login to unlock the full suite of MEDICALLY features
Mar 6
/
Roche and Genentech
Resistance mechanisms and efficacy of first-line alectinib in patients with ALK+ non-small cell lung cancer
ALCURE is a real-world, observational, multi-center study exploring resistance mechanisms to first-line alectinib, prognostic factors of the efficacy of alectinib and optimal treatment sequencing in patients with advanced ALK-positive NSCLC. This oral presentation presents efficacy data with first-line alectinib and resistance mechanisms to alectinib from the second interim analysis of the ALCURE study.
Sign up or login to unlock the full suite of MEDICALLY features
Mar 6
/
Roche and Genentech
Pharmacokinetics and safety of adjuvant alectinib in Japanese patients (pts) from ALINA with resected ALK-positive NSCLC
ALINA: Subgroup analysis investigating the pharmacokinetics and safety of adjuvant alectinib in Japanese patients with resectable stage IB-IIIA (UICC/AJCC 7th edition) ALK-positive NSCLC.